■长期使用局部抗青光眼药物通常与眼表毒性有关,这会影响患者的药物依从性和生活质量。这项研究评估了这些药物的效果,采用细胞学改变的结膜和眼表症状。
■这是一家诊所,在拉各斯大学教学医院进行的病例对照研究,比较了接受局部用药的青光眼患者与年龄性别匹配的对照。对照组是非青光眼患者,他们在研究前至少6个月没有服用任何局部眼部药物。眼表疾病指数(OSDI)问卷用于评估眼表症状。Schirmer\'sItest,泪膜破裂时间(TBUT)测试和眼表角膜荧光素染色用于眼表疾病(OSD)评估和结膜印模细胞学(CIC)用于组织学评估和分级。
■348名受访者的六百九十六只眼睛,174个病例和174个对照,进行OSD评估。病例组和对照组的平均年龄分别为56.3±12.9岁和55.5±13.2岁,分别,差异无统计学意义(P=0.589)。与对照组相比,病例组中评估的所有眼部参数均显着异常。使用局部抗青光眼药物与TBUT异常显着相关(P<0.001),Schirmer检验(P<0.001),眼表染色(P<0.001),CIC(P<0.001)和OSDI评分(P=0.001)。异常TBUT与药物数量之间存在显着关联(P=0.044,比值比[OR]=0.79,95%置信区间[CI]:0.44-1.14),在异常眼表染色和抗青光眼药物使用时间之间(P=0.0104,OR=1.2,95%CI:1.04-1.43)以及异常CIC和抗青光眼药物使用时间之间(P=0.0007,OR=0.7,95%CI:0.59-0.86)。
该研究表明,长期使用局部抗青光眼药物可能与眼表结构损伤有关。
UNASSIGNED: The long-term use of topical anti-glaucoma medications is often associated with ocular surface toxicity that can affect the patient\'s drug compliance and quality of life. This study assessed the effect of these medications, using cytological changes of the conjunctiva and ocular surface symptoms.
UNASSIGNED: This was a clinic-based,
case-control study that was conducted at the Lagos University Teaching Hospital that compared glaucoma patients on topical medications with age-sex-matched controls. The controls were non-glaucoma patients, who were not on any topical ocular medications at least 6 months prior to the study. The Ocular Surface Disease Index (OSDI) questionnaire was used to assess ocular surface symptoms. Schirmer\'s I test, tear film break-up time (TBUT) test and corneal fluorescein staining of the ocular surface were used for ocular surface disease (OSD) assessment and conjunctival impression cytology (CIC) for histological assessment and grading.
UNASSIGNED: Six hundred and ninety-six eyes of 348 respondents, 174 cases and 174 controls, were assessed for OSD. The mean ages of the
case and control groups were 56.3 ± 12.9 years and 55.5 ± 13.2 years, respectively, with no statistical difference (P = 0.589). All ocular parameters assessed were significantly abnormal in the
case group compared to the control group. The use of topical anti-glaucoma medications was significantly associated with abnormal TBUT (P < 0.001), Schirmer\'s test (P < 0.001), ocular surface staining (P < 0.001), CIC (P < 0.001) and OSDI scores (P = 0.001). A significant association was seen between abnormal TBUT and the number of medications (P = 0.044, odds ratio [OR] =0.79, 95% confidence interval [CI]: 0.44-1.14), between abnormal ocular surface staining and duration of anti-glaucoma medications usage (P = 0.0104, OR = 1.2, 95% CI: 1.04-1.43) and between abnormal CIC and the duration of anti-glaucoma medications (P = 0.0007, OR = 0.7, 95% CI: 0.59-0.86).
UNASSIGNED: The study demonstrates that prolonged use of topical anti-glaucoma medications may be associated with damage to the ocular surface structures.